FDA review clears path for second coronavirus vaccine, this one developed by ModernaDavid OjciusDec 15, 20201 min readBy the end of the week, the US could have 2 #coronavirus vaccines.An FDA review clears path for the coronavirus vaccine, developed by Moderna. Regulators, who confirmed the vaccine was 94% effective, could authorize it as early as Friday.#Moderna #COVID19 #vaccines #infectionhttps://www.washingtonpost.com/health/2020/12/15/moderna-vaccine-found-safe-effective/?wpmk=1&wpisrc=al_news__alert-hse--alert-national&utm_source=alert&utm_medium=email&utm_campaign=wp_news_alert_revere&location=alert&pwapi_token=eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJjb29raWVuYW1lIjoid3BfY3J0aWQiLCJpc3MiOiJDYXJ0YSIsImNvb2tpZXZhbHVlIjoiNTk3NmEwZmM5YmJjMGY2ODI2YjhjMDUwIiwidGFnIjoid3BfbmV3c19hbGVydF9yZXZlcmUiLCJ1cmwiOiJodHRwczovL3d3dy53YXNoaW5ndG9ucG9zdC5jb20vaGVhbHRoLzIwMjAvMTIvMTUvbW9kZXJuYS12YWNjaW5lLWZvdW5kLXNhZmUtZWZmZWN0aXZlLz93cG1rPTEmd3Bpc3JjPWFsX25ld3NfX2FsZXJ0LWhzZS0tYWxlcnQtbmF0aW9uYWwmdXRtX3NvdXJjZT1hbGVydCZ1dG1fbWVkaXVtPWVtYWlsJnV0bV9jYW1wYWlnbj13cF9uZXdzX2FsZXJ0X3JldmVyZSZsb2NhdGlvbj1hbGVydCJ9.g9GTh2UClGbS23Xs127DJ9ZYcYL36XpHQzyWOxcaW04
By the end of the week, the US could have 2 #coronavirus vaccines.An FDA review clears path for the coronavirus vaccine, developed by Moderna. Regulators, who confirmed the vaccine was 94% effective, could authorize it as early as Friday.#Moderna #COVID19 #vaccines #infectionhttps://www.washingtonpost.com/health/2020/12/15/moderna-vaccine-found-safe-effective/?wpmk=1&wpisrc=al_news__alert-hse--alert-national&utm_source=alert&utm_medium=email&utm_campaign=wp_news_alert_revere&location=alert&pwapi_token=eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJjb29raWVuYW1lIjoid3BfY3J0aWQiLCJpc3MiOiJDYXJ0YSIsImNvb2tpZXZhbHVlIjoiNTk3NmEwZmM5YmJjMGY2ODI2YjhjMDUwIiwidGFnIjoid3BfbmV3c19hbGVydF9yZXZlcmUiLCJ1cmwiOiJodHRwczovL3d3dy53YXNoaW5ndG9ucG9zdC5jb20vaGVhbHRoLzIwMjAvMTIvMTUvbW9kZXJuYS12YWNjaW5lLWZvdW5kLXNhZmUtZWZmZWN0aXZlLz93cG1rPTEmd3Bpc3JjPWFsX25ld3NfX2FsZXJ0LWhzZS0tYWxlcnQtbmF0aW9uYWwmdXRtX3NvdXJjZT1hbGVydCZ1dG1fbWVkaXVtPWVtYWlsJnV0bV9jYW1wYWlnbj13cF9uZXdzX2FsZXJ0X3JldmVyZSZsb2NhdGlvbj1hbGVydCJ9.g9GTh2UClGbS23Xs127DJ9ZYcYL36XpHQzyWOxcaW04
Genomic signatures and host adaptation of H5N1 clade 2.3.4.4b: A call for global surveillance and multi-target antiviral strategies
Journée d’échanges et restitution du projet : EQUIPer les ACTeurs pour plus d’impacts dans les transitions (ANR Equipact)
Komentáře